Steven AR Murphy: Urolithin A Shows Immune Rejuvenation and Mitochondrial Benefits in New Trial
Steven AR Murphy, Medical Director, Concierge Medical Associates, shared a post on LinkedIn:
”A Change in Urolithin A Dosing: What the Latest Human Data Means for Longevity Medicine
For years, Urolithin A has intrigued longevity researchers as a gut-derived molecule capable of activating mitophagy, the process of recycling worn-out mitochondria. In essence, it’s cellular housekeeping: clearing broken power plants so new ones can thrive.
Many of our patients take this for it’s Mitophagy benefit.
A newly published Nature Aging randomized, placebo-controlled trial has now brought real human evidence to the table. In just 28 days, healthy adults aged 45–70 who took 1,000 mg of Urolithin A daily showed clear biologic signs of immune rejuvenation and improved mitochondrial metabolism—with excellent safety.
Here’s what changed:
T cells looked and acted younger, with more naive-like CD8 cells and lower exhaustion markers.
Immune metabolism rewired, favoring fatty acid and amino acid oxidation (a signature of healthier, more resilient immunity).
Mitochondrial programs activated, including upregulation of PGC-1α, the master regulator of energy biogenesis.
From a clinical perspective, the data justify what we’re now implementing at Concierge Medical Associates.
While the study didn’t include a 500 mg arm, 1,000 mg is the only dose shown to move the biological levers of aging in humans.
If your goal is to enhance mitochondrial resilience, immune performance, and long-term vitality, this represents a practice-changing moment in longevity medicine and you can read my full analysis—including how I’m adjusting protocols—in the latest Longevity Insider with Dr. Murphy post here.”
Stay updated with Hemostasis Today.
-
Oct 4, 2026, 15:06Vasiliki Gkalea: Journal of Clinical Medicine Launches Special Issue on Hematologic Thrombosis and Bleeding
-
Oct 4, 2026, 14:55Quentin Brebant: What Defines a High-Quality Red Blood Cell Concentrate?
-
Oct 4, 2026, 14:47Rana Al-Hrout: Recognizing Non-Anemic Iron Deficiency – Why Iron Matters Beyond Hemoglobin
-
Oct 4, 2026, 14:41David McIntosh: International Plasma Awareness Week 2026 – Closing the Global Plasma Gap
-
Oct 4, 2026, 14:33Pete Stibbs: CleanerVac Real-World Study Presented at VIVA and The VEINS 2026
-
Oct 4, 2026, 13:56Maria Elisa Mancuso: EHC 2026 Highlights the Unmet Needs of Women with Bleeding Disorders
-
Oct 4, 2026, 13:53Nirmal Shaji George: Individualizing Anticoagulation in Complex APS and Thrombocytopenia
-
Oct 4, 2026, 13:5210 Posts Not to Miss This Week
-
Oct 4, 2026, 13:45Suswapna Singh Rawat: The Clinical Significance of Coronary Plaque Stability